Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23092737 | 1.00 | LMNA (0.44) | LMNATBXAS1RIPK1CYP3A4KDM4E | |
| SCHEMBL29715367 | 1.00 | LMNA (0.44) | LMNATBXAS1RIPK1CYP3A4KDM4E | |
| SCHEMBL25178693 | 0.89 | CYP3A4 (0.44) | LMNATBXAS1RIPK1CYP3A4KDM4E | |
| SCHEMBL23092647 | 0.88 | CYP3A4 (0.42) | LMNARIPK1CYP3A4MMP13FDPS | |
| SCHEMBL23092645 | 0.88 | CYP3A4 (0.42) | LMNARIPK1CYP3A4MMP13FDPS | |
| SCHEMBL29715349 | 0.88 | CYP3A4 (0.42) | LMNARIPK1CYP3A4MMP13FDPS | |
| SCHEMBL29166084 | 0.86 | LMNA (0.47) | LMNATBXAS1CYP3A4KDM4ENAPRT | |
| SCHEMBL1401042 | 0.86 | MMP13 (0.46) | MMP13MMP9MMP2 | |
| SCHEMBL2476924 | 0.86 | MMP13 (0.46) | MMP13MMP9MMP2 | |
| SCHEMBL65502 | 0.86 | MMP13 (0.46) | MMP13MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-1807443-A1 | ACYLATED NONADEPSIPEPTIDES USED AS LYSOBACTIN DERIVATIVES | AiCuris GmbH & Co. KG (DE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006048139-A1 | ACYLATED NONADEPSIPEPTIDES USED AS LYSOBACTIN DERIVATIVES | AICURIS GMBH & CO. KG (DE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | LMNA 3682/4885TBXAS1 3478/4885RIPK1 1424/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | LMNA 3682/4885TBXAS1 3478/4885RIPK1 1424/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | LMNA 3682/4885TBXAS1 3478/4885RIPK1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.